This is default featured slide 1 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.

This is default featured slide 2 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.

This is default featured slide 3 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.

This is default featured slide 4 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.

This is default featured slide 5 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.

Saturday, May 12, 2012

Health News Watchdog rejects colon hydrotherapy offer

Just last month I first wrote that some of these Groupon-like offers are getting a little crazy.

Now,within the past 24 hours,I’ve seen Groupon-like offers for:

laser toenail fungus treatment (evidence questionable), another MRI scan offer for “headache prevention screening” (!!??!!).

But my favorite was a Living Social offer for Colon Hydrotherapy, with this ad copy:

The foliage may be in bloom outside, but if you’re feeling less than fresh inside, today’s deal  could help you stem the problem: Pay $35 and get one colon hydrotherapy session (a $75 value). Colon hydrotherapy is a safe, effective method of cleansing the large intestine using water instead of drugs. The gentle infusion of warm filtered water moves naturally through your large intestine, leaving you feeling cleansed and refreshed. The treatment is safe, quick and pain-free. The certified staff uses an advanced state-of-the-art technology to provide you with natural wellness therapies. Don’t be a shrinking violet — nab today’s deal before it goes to seed.

No, thanks.  I don’t feel an urgent need for my large intestine to feel cleansed and refreshed by state-of-the-art technology.

This shrinking violet’s colon is just fine without hydrotherapy hype.

Addendum on April 27:  Add two more that just came in today’s email.

Addendum on April 30:  Why not just keep adding to this hilarious list:



View the original article here

Health News Watchdog rejects colon hydrotherapy offer

Just last month I first wrote that some of these Groupon-like offers are getting a little crazy.

Now,within the past 24 hours,I’ve seen Groupon-like offers for:

laser toenail fungus treatment (evidence questionable), another MRI scan offer for “headache prevention screening” (!!??!!).

But my favorite was a Living Social offer for Colon Hydrotherapy, with this ad copy:

The foliage may be in bloom outside, but if you’re feeling less than fresh inside, today’s deal  could help you stem the problem: Pay $35 and get one colon hydrotherapy session (a $75 value). Colon hydrotherapy is a safe, effective method of cleansing the large intestine using water instead of drugs. The gentle infusion of warm filtered water moves naturally through your large intestine, leaving you feeling cleansed and refreshed. The treatment is safe, quick and pain-free. The certified staff uses an advanced state-of-the-art technology to provide you with natural wellness therapies. Don’t be a shrinking violet — nab today’s deal before it goes to seed.

No, thanks.  I don’t feel an urgent need for my large intestine to feel cleansed and refreshed by state-of-the-art technology.

This shrinking violet’s colon is just fine without hydrotherapy hype.

Addendum on April 27:  Add two more that just came in today’s email.

Addendum on April 30:  Why not just keep adding to this hilarious list:



View the original article here

Health News Watchdog rejects colon hydrotherapy offer

Just last month I first wrote that some of these Groupon-like offers are getting a little crazy.

Now,within the past 24 hours,I’ve seen Groupon-like offers for:

laser toenail fungus treatment (evidence questionable), another MRI scan offer for “headache prevention screening” (!!??!!).

But my favorite was a Living Social offer for Colon Hydrotherapy, with this ad copy:

The foliage may be in bloom outside, but if you’re feeling less than fresh inside, today’s deal  could help you stem the problem: Pay $35 and get one colon hydrotherapy session (a $75 value). Colon hydrotherapy is a safe, effective method of cleansing the large intestine using water instead of drugs. The gentle infusion of warm filtered water moves naturally through your large intestine, leaving you feeling cleansed and refreshed. The treatment is safe, quick and pain-free. The certified staff uses an advanced state-of-the-art technology to provide you with natural wellness therapies. Don’t be a shrinking violet — nab today’s deal before it goes to seed.

No, thanks.  I don’t feel an urgent need for my large intestine to feel cleansed and refreshed by state-of-the-art technology.

This shrinking violet’s colon is just fine without hydrotherapy hype.

Addendum on April 27:  Add two more that just came in today’s email.

Addendum on April 30:  Why not just keep adding to this hilarious list:



View the original article here

iLuv Your iPad – Giveaway

pink ipad case iLuv Your iPad GiveawayI am the “mom” to a brand-new iPad (the 2, since the 3 hadn’t yet come out), and I’m super-protective of it.  My kids and husband pretty much took over my original iPad, and this one is all mine!  I’ve eliminated the tons of games my kids download, and it has all of my stuff on it.  Since I plan to take care of this one so it stays nice, I was thrilled to get an iLuv kit to keep it looking great.

Here’s what the kit includes:

iCC845 Epicarp folio cover in pink- similar to the Apple ipad case, this one also offers protection for the back.  It also folds nicer than the Apple case, and is bright and colorful.

iEP325 Calvados High-Fidelity Earphones with SpeakEZ Remote for iPod / iPhone / iPad in pink- these earphones are small and easy to carry along with me.  They also work for the iPhone too.

iCL45 screen cleaner for electronic devices. Even though my kids’ little fingers don’t touch my iPad (at least I don’t think they do), the screen still gets pretty gross.  So, I am loving this screen cleaner.

You can learn more about iLuv iPad products at their website.

Win it!  Do you want to win this same kit?  Enter via the Rafflecopter.  Giveaway ends 5/17 at 12:01am and includes the iPad cover, the screen cleaner, and the earphones.
a Rafflecopter giveaway

Disclosure: I received this set at no cost for review.

pixel iLuv Your iPad Giveaway Tagged as: iPad


View the original article here

Health News Watchdog rejects colon hydrotherapy offer

Just last month I first wrote that some of these Groupon-like offers are getting a little crazy.

Now,within the past 24 hours,I’ve seen Groupon-like offers for:

laser toenail fungus treatment (evidence questionable), another MRI scan offer for “headache prevention screening” (!!??!!).

But my favorite was a Living Social offer for Colon Hydrotherapy, with this ad copy:

The foliage may be in bloom outside, but if you’re feeling less than fresh inside, today’s deal  could help you stem the problem: Pay $35 and get one colon hydrotherapy session (a $75 value). Colon hydrotherapy is a safe, effective method of cleansing the large intestine using water instead of drugs. The gentle infusion of warm filtered water moves naturally through your large intestine, leaving you feeling cleansed and refreshed. The treatment is safe, quick and pain-free. The certified staff uses an advanced state-of-the-art technology to provide you with natural wellness therapies. Don’t be a shrinking violet — nab today’s deal before it goes to seed.

No, thanks.  I don’t feel an urgent need for my large intestine to feel cleansed and refreshed by state-of-the-art technology.

This shrinking violet’s colon is just fine without hydrotherapy hype.

Addendum on April 27:  Add two more that just came in today’s email.

Addendum on April 30:  Why not just keep adding to this hilarious list:



View the original article here

Health News Watchdog rejects colon hydrotherapy offer

Just last month I first wrote that some of these Groupon-like offers are getting a little crazy.

Now,within the past 24 hours,I’ve seen Groupon-like offers for:

laser toenail fungus treatment (evidence questionable), another MRI scan offer for “headache prevention screening” (!!??!!).

But my favorite was a Living Social offer for Colon Hydrotherapy, with this ad copy:

The foliage may be in bloom outside, but if you’re feeling less than fresh inside, today’s deal  could help you stem the problem: Pay $35 and get one colon hydrotherapy session (a $75 value). Colon hydrotherapy is a safe, effective method of cleansing the large intestine using water instead of drugs. The gentle infusion of warm filtered water moves naturally through your large intestine, leaving you feeling cleansed and refreshed. The treatment is safe, quick and pain-free. The certified staff uses an advanced state-of-the-art technology to provide you with natural wellness therapies. Don’t be a shrinking violet — nab today’s deal before it goes to seed.

No, thanks.  I don’t feel an urgent need for my large intestine to feel cleansed and refreshed by state-of-the-art technology.

This shrinking violet’s colon is just fine without hydrotherapy hype.

Addendum on April 27:  Add two more that just came in today’s email.

Addendum on April 30:  Why not just keep adding to this hilarious list:



View the original article here

Health News Watchdog rejects colon hydrotherapy offer

Just last month I first wrote that some of these Groupon-like offers are getting a little crazy.

Now,within the past 24 hours,I’ve seen Groupon-like offers for:

laser toenail fungus treatment (evidence questionable), another MRI scan offer for “headache prevention screening” (!!??!!).

But my favorite was a Living Social offer for Colon Hydrotherapy, with this ad copy:

The foliage may be in bloom outside, but if you’re feeling less than fresh inside, today’s deal  could help you stem the problem: Pay $35 and get one colon hydrotherapy session (a $75 value). Colon hydrotherapy is a safe, effective method of cleansing the large intestine using water instead of drugs. The gentle infusion of warm filtered water moves naturally through your large intestine, leaving you feeling cleansed and refreshed. The treatment is safe, quick and pain-free. The certified staff uses an advanced state-of-the-art technology to provide you with natural wellness therapies. Don’t be a shrinking violet — nab today’s deal before it goes to seed.

No, thanks.  I don’t feel an urgent need for my large intestine to feel cleansed and refreshed by state-of-the-art technology.

This shrinking violet’s colon is just fine without hydrotherapy hype.

Addendum on April 27:  Add two more that just came in today’s email.

Addendum on April 30:  Why not just keep adding to this hilarious list:



View the original article here

VTech’s Multitasking Phone System – the LS6475-3

As a busy multitasking, work at home mom, I try to schedule all of my phone calls for the five hours that my kids are in school.  But occasionally, I do have to take a call after school, which means that I’m usually juggling five things at one time.  I’m almost always asked to open a package, turn on a TV station, provide a snack, or do something else that my little kiddies need.  That’s why the VTech LS6475-3 Multitasking phone system works well for me, because I can be completely hands free as I take my calls.

The VTech LS6475-3 phone system includes a base station and a phone base.  The base station includes an answering machine (which I don’t need, so I turn it off), and the whole system can be expanded to accommodate 12 handsets.  A hands-free headset is also included, which you can just clip over your ear to take your calls.  One additional hands-free headset can also be added to the system.

My favorite feature is the voice announce caller ID – when the phone tells me that the call is from “Not Available”, I don’t even have to get up from the couch to answer it!  The system also offers push to talk functionality, DECT 6.0 digital technology, a 500 foot range, and a sleek, stylish appearance.  It’s a great phone system for any mom that needs to be hands free at times (and let’s face it – that’s all moms!), and since it’s expandable, it can be used throughout the entire home.

Visit the VTech LS6475-3 Multitasking Phone system product page, the VTech Facebook page, and the VTech Twitter page for more information on the VTech LS6475-3.

Disclosure: I wrote this review while participating in a campaign by Mom Central Consulting on behalf of VTech and received a product sample to facilitate my review.

pixel VTechs Multitasking Phone System the LS6475 3 Tagged as: home office, phone systems


View the original article here

Steer Me Steve Review and Giveaway

FamilyClub 300x224 Steer Me Steve Review and Giveaway

As the mom to a little guy, I know that most boys love trucks and building.  My little guy used to love MEGA Bloks, and actually still really enjoys building and playing with trucks.  So, he’s still having lots of fun playing with the Steer-me Steve Dump Truck by MEGA Bloks that we received.  It’s a great toy for little guys because it’s bright, colorful, and large enough for little hands to maneuver.  Your little guy will love scooping up blocks, dumping them, and starting all over again.

SteermeSteve 300x233 Steer Me Steve Review and GiveawayFrom MEGA Bloks, here are some of the product features:

• Easy grip plastic steer along steering wheel
• Quick pull lever to empty cargo
• Fun, colorful design
• Includes 7 big Maxi blocks
• Cheerful, friendly face

Age Range: 1-4
Price: $19.99
‘Like’ Mega Bloks on Facebook
View the Steer Me Steve product page

Win it!  I have one Steer Me Steve truck to giveaway to one lucky Mom’s Favorite Stuff reader.  Enter via the Rafflecopter.  Giveaway ends 12:01am at 5/15/12.  Prizing courtesy of MEGA Bloks.  Contest open to US mailing addresses only


a Rafflecopter giveaway

Disclosure: I received a Steer Me Steve at no cost for review.

pixel Steer Me Steve Review and Giveaway Tagged as: MEGA bloks


View the original article here

Analysis of two Annals papers on benefits of mammography in younger women

Results of two studies published in the Annals of Internal Medicine point to benefits of biennial mammography screening starting age 40 for women at increased risk.

One evaluated data from 66 published articles and from the Breast Cancer Surveillance Consortium.  The authors’ conclusion:

The second study tried to assess “tipping the balance of benefits and harms to favor screening mammography starting at age 40.”  The lead author concluded:

“The evidence suggests that for women at twice the average risk for breast cancer, biennial screening beginning at age 40 has more benefits than harms,” said study lead author Nicolien T. van Ravesteyn, MSc, of the Department of Public Health, Erasmus MC, Rotterdam, The Netherlands. “These results provide important information toward developing more individualized, risk-based screening guidelines.”

Dr. Otis Brawley, chief medical and scientific officer of the American Cancer Society, wrote an accompanying editorial.  Excerpts:

“I worry that the public perceives mammography as a better technology than it actually is. Mammography screening is often promoted for its benefit. Unfortunately, many do not appreciate its limitations. Truth be told, it cannot avert all or even most breast cancer deaths. There are also tradeoffs. Mammography, like every screening test, has a potential for harm, and one must carefully weigh the harm–benefit ratio for a specific woman or a specific population of women (such as those aged 40 to 49 years) before advising use of the test. The harms associated with mammographic screening include false-positive results, false-positive biopsy results, radiation exposure, false-negative results and false reassurance, pain related to the procedure, overdiagnosis (that is, diagnosis of tumors that are of no threat), and overtreatment. False-positive results are the most common and easily quantifiable harm. On the basis of statistics specific to U.S. practice patterns, about half of women getting an annual mammogram for 10 years starting at age 40 years will have at least 1 false-positive result that requires additional testing. More than 5% will get a biopsy during that time.

…These studies also demonstrate that questions about annual versus biennial screening are legitimate but unsettled. The Cancer Intervention and Surveillance Modeling Network consistently shows that annual screening of women in their 40s marginally increases the number of lives saved while substantially increasing harms. This means that patients and their physicians need to make value judgments regarding the harms and benefits.
In the future, more emphasis will be placed on riskbased screening guidelines tailored to the individual. There may be recommendations that some women at very high risk get annual testing, some at intermediate risk get biennial testing, and some at normal risk start screening at a later age. This will be challenging because many health care providers and members of the lay community do not understand screening and the concept of risk. Specific tools designed to educate them need to be developed and rigorously assessed. Ultimately, the preferences of individual women, recognizing the potential for harm and benefit, should be respected.”

For more perspective, I asked Russell Harris, MD, MPH of the University of North Carolina, to analyze the new studies.  He wrote:

“These are well-conducted studies that try to move us toward more efficient screening for breast cancer.  Certainly we are all in favor of that.  At present, our screening is based on the fact that the risk of breast cancer and breast cancer mortality increases with age; thus, we base starting screening on age.  This is the famous “start at age 40 vs start at age 50” debate we have been having for many years.  These investigators suggest that perhaps there are risk factors beyond age that could allow us to better target the women who could benefit from screening.  It is a good idea.

Unfortunately, the first paper (Nelson et al) shows that we just don’t know enough about the factors that increase or decrease the risk of breast cancer to be able to use this proposed strategy.  This causes the second paper (van Ravesteyn) to make some statements that may be misunderstood and confusing.

Nelson (the first paper) systematically reviews studies of the risk of breast cancer, finding that, other than age, extremely dense breasts on mammogram and presence of first-degree family history of breast cancer are the most important risk factors.  It is important to know that dense breasts on mammography may well reduce the ability of mammography to detect breast cancer, and that very few women will have 2 or more first degree relatives who have been diagnosed with breast cancer (which is the group that has a really substantial increased risk).  The problem is that neither of these factors increase risk more than about two-fold.  These factors would be much more useful if they increased risk by 15 or 20-fold.

Van Ravesteyn et al (the second paper) then use their models to find that if we could identify women in their 40s whose risk is more than 3 times usual risk, then the number of lives extended by screening those women in their 40s would be about the same as the number in their 50s whose lives are extended by screening.  (In neither case is this a large number of women.)  Unfortunately, they do not adequately address the issue of the harms of screening, especially including overdiagnosis, a problem that many people far underestimate. Because the models do not adequately address harms, and because we don’t know how much benefit there would be (if any) from screening women in their 40s with dense breasts, and because there are so few women in their 40s with 2 or more first degree relatives, this strategy really doesn’t get us very far toward making screening more efficient.  The best strategy is still what the USPSTF recommended: individual discussions between patient and medical team to develop an individual approach.

Some people who have wanted to start screening mammography at age 40 will read these papers and find a justification for starting early.  A better interpretation of these studies is that we still need better risk tools that help us become more efficient with breast cancer screening – and this means not only finding women whose risk is high enough that screening makes good sense AND also finding women in their 50s and 60s whose risk is low enough that screening doesn’t make sense.  Then we can truly say we are more efficient – screening women more likely to benefit and NOT screening women more likely to be harmed.”


View the original article here

Analysis of two Annals papers on benefits of mammography in younger women

Results of two studies published in the Annals of Internal Medicine point to benefits of biennial mammography screening starting age 40 for women at increased risk.

One evaluated data from 66 published articles and from the Breast Cancer Surveillance Consortium.  The authors’ conclusion:

The second study tried to assess “tipping the balance of benefits and harms to favor screening mammography starting at age 40.”  The lead author concluded:

“The evidence suggests that for women at twice the average risk for breast cancer, biennial screening beginning at age 40 has more benefits than harms,” said study lead author Nicolien T. van Ravesteyn, MSc, of the Department of Public Health, Erasmus MC, Rotterdam, The Netherlands. “These results provide important information toward developing more individualized, risk-based screening guidelines.”

Dr. Otis Brawley, chief medical and scientific officer of the American Cancer Society, wrote an accompanying editorial.  Excerpts:

“I worry that the public perceives mammography as a better technology than it actually is. Mammography screening is often promoted for its benefit. Unfortunately, many do not appreciate its limitations. Truth be told, it cannot avert all or even most breast cancer deaths. There are also tradeoffs. Mammography, like every screening test, has a potential for harm, and one must carefully weigh the harm–benefit ratio for a specific woman or a specific population of women (such as those aged 40 to 49 years) before advising use of the test. The harms associated with mammographic screening include false-positive results, false-positive biopsy results, radiation exposure, false-negative results and false reassurance, pain related to the procedure, overdiagnosis (that is, diagnosis of tumors that are of no threat), and overtreatment. False-positive results are the most common and easily quantifiable harm. On the basis of statistics specific to U.S. practice patterns, about half of women getting an annual mammogram for 10 years starting at age 40 years will have at least 1 false-positive result that requires additional testing. More than 5% will get a biopsy during that time.

…These studies also demonstrate that questions about annual versus biennial screening are legitimate but unsettled. The Cancer Intervention and Surveillance Modeling Network consistently shows that annual screening of women in their 40s marginally increases the number of lives saved while substantially increasing harms. This means that patients and their physicians need to make value judgments regarding the harms and benefits.
In the future, more emphasis will be placed on riskbased screening guidelines tailored to the individual. There may be recommendations that some women at very high risk get annual testing, some at intermediate risk get biennial testing, and some at normal risk start screening at a later age. This will be challenging because many health care providers and members of the lay community do not understand screening and the concept of risk. Specific tools designed to educate them need to be developed and rigorously assessed. Ultimately, the preferences of individual women, recognizing the potential for harm and benefit, should be respected.”

For more perspective, I asked Russell Harris, MD, MPH of the University of North Carolina, to analyze the new studies.  He wrote:

“These are well-conducted studies that try to move us toward more efficient screening for breast cancer.  Certainly we are all in favor of that.  At present, our screening is based on the fact that the risk of breast cancer and breast cancer mortality increases with age; thus, we base starting screening on age.  This is the famous “start at age 40 vs start at age 50” debate we have been having for many years.  These investigators suggest that perhaps there are risk factors beyond age that could allow us to better target the women who could benefit from screening.  It is a good idea.

Unfortunately, the first paper (Nelson et al) shows that we just don’t know enough about the factors that increase or decrease the risk of breast cancer to be able to use this proposed strategy.  This causes the second paper (van Ravesteyn) to make some statements that may be misunderstood and confusing.

Nelson (the first paper) systematically reviews studies of the risk of breast cancer, finding that, other than age, extremely dense breasts on mammogram and presence of first-degree family history of breast cancer are the most important risk factors.  It is important to know that dense breasts on mammography may well reduce the ability of mammography to detect breast cancer, and that very few women will have 2 or more first degree relatives who have been diagnosed with breast cancer (which is the group that has a really substantial increased risk).  The problem is that neither of these factors increase risk more than about two-fold.  These factors would be much more useful if they increased risk by 15 or 20-fold.

Van Ravesteyn et al (the second paper) then use their models to find that if we could identify women in their 40s whose risk is more than 3 times usual risk, then the number of lives extended by screening those women in their 40s would be about the same as the number in their 50s whose lives are extended by screening.  (In neither case is this a large number of women.)  Unfortunately, they do not adequately address the issue of the harms of screening, especially including overdiagnosis, a problem that many people far underestimate. Because the models do not adequately address harms, and because we don’t know how much benefit there would be (if any) from screening women in their 40s with dense breasts, and because there are so few women in their 40s with 2 or more first degree relatives, this strategy really doesn’t get us very far toward making screening more efficient.  The best strategy is still what the USPSTF recommended: individual discussions between patient and medical team to develop an individual approach.

Some people who have wanted to start screening mammography at age 40 will read these papers and find a justification for starting early.  A better interpretation of these studies is that we still need better risk tools that help us become more efficient with breast cancer screening – and this means not only finding women whose risk is high enough that screening makes good sense AND also finding women in their 50s and 60s whose risk is low enough that screening doesn’t make sense.  Then we can truly say we are more efficient – screening women more likely to benefit and NOT screening women more likely to be harmed.”


View the original article here

Analysis of two Annals papers on benefits of mammography in younger women

Results of two studies published in the Annals of Internal Medicine point to benefits of biennial mammography screening starting age 40 for women at increased risk.

One evaluated data from 66 published articles and from the Breast Cancer Surveillance Consortium.  The authors’ conclusion:

The second study tried to assess “tipping the balance of benefits and harms to favor screening mammography starting at age 40.”  The lead author concluded:

“The evidence suggests that for women at twice the average risk for breast cancer, biennial screening beginning at age 40 has more benefits than harms,” said study lead author Nicolien T. van Ravesteyn, MSc, of the Department of Public Health, Erasmus MC, Rotterdam, The Netherlands. “These results provide important information toward developing more individualized, risk-based screening guidelines.”

Dr. Otis Brawley, chief medical and scientific officer of the American Cancer Society, wrote an accompanying editorial.  Excerpts:

“I worry that the public perceives mammography as a better technology than it actually is. Mammography screening is often promoted for its benefit. Unfortunately, many do not appreciate its limitations. Truth be told, it cannot avert all or even most breast cancer deaths. There are also tradeoffs. Mammography, like every screening test, has a potential for harm, and one must carefully weigh the harm–benefit ratio for a specific woman or a specific population of women (such as those aged 40 to 49 years) before advising use of the test. The harms associated with mammographic screening include false-positive results, false-positive biopsy results, radiation exposure, false-negative results and false reassurance, pain related to the procedure, overdiagnosis (that is, diagnosis of tumors that are of no threat), and overtreatment. False-positive results are the most common and easily quantifiable harm. On the basis of statistics specific to U.S. practice patterns, about half of women getting an annual mammogram for 10 years starting at age 40 years will have at least 1 false-positive result that requires additional testing. More than 5% will get a biopsy during that time.

…These studies also demonstrate that questions about annual versus biennial screening are legitimate but unsettled. The Cancer Intervention and Surveillance Modeling Network consistently shows that annual screening of women in their 40s marginally increases the number of lives saved while substantially increasing harms. This means that patients and their physicians need to make value judgments regarding the harms and benefits.
In the future, more emphasis will be placed on riskbased screening guidelines tailored to the individual. There may be recommendations that some women at very high risk get annual testing, some at intermediate risk get biennial testing, and some at normal risk start screening at a later age. This will be challenging because many health care providers and members of the lay community do not understand screening and the concept of risk. Specific tools designed to educate them need to be developed and rigorously assessed. Ultimately, the preferences of individual women, recognizing the potential for harm and benefit, should be respected.”

For more perspective, I asked Russell Harris, MD, MPH of the University of North Carolina, to analyze the new studies.  He wrote:

“These are well-conducted studies that try to move us toward more efficient screening for breast cancer.  Certainly we are all in favor of that.  At present, our screening is based on the fact that the risk of breast cancer and breast cancer mortality increases with age; thus, we base starting screening on age.  This is the famous “start at age 40 vs start at age 50” debate we have been having for many years.  These investigators suggest that perhaps there are risk factors beyond age that could allow us to better target the women who could benefit from screening.  It is a good idea.

Unfortunately, the first paper (Nelson et al) shows that we just don’t know enough about the factors that increase or decrease the risk of breast cancer to be able to use this proposed strategy.  This causes the second paper (van Ravesteyn) to make some statements that may be misunderstood and confusing.

Nelson (the first paper) systematically reviews studies of the risk of breast cancer, finding that, other than age, extremely dense breasts on mammogram and presence of first-degree family history of breast cancer are the most important risk factors.  It is important to know that dense breasts on mammography may well reduce the ability of mammography to detect breast cancer, and that very few women will have 2 or more first degree relatives who have been diagnosed with breast cancer (which is the group that has a really substantial increased risk).  The problem is that neither of these factors increase risk more than about two-fold.  These factors would be much more useful if they increased risk by 15 or 20-fold.

Van Ravesteyn et al (the second paper) then use their models to find that if we could identify women in their 40s whose risk is more than 3 times usual risk, then the number of lives extended by screening those women in their 40s would be about the same as the number in their 50s whose lives are extended by screening.  (In neither case is this a large number of women.)  Unfortunately, they do not adequately address the issue of the harms of screening, especially including overdiagnosis, a problem that many people far underestimate. Because the models do not adequately address harms, and because we don’t know how much benefit there would be (if any) from screening women in their 40s with dense breasts, and because there are so few women in their 40s with 2 or more first degree relatives, this strategy really doesn’t get us very far toward making screening more efficient.  The best strategy is still what the USPSTF recommended: individual discussions between patient and medical team to develop an individual approach.

Some people who have wanted to start screening mammography at age 40 will read these papers and find a justification for starting early.  A better interpretation of these studies is that we still need better risk tools that help us become more efficient with breast cancer screening – and this means not only finding women whose risk is high enough that screening makes good sense AND also finding women in their 50s and 60s whose risk is low enough that screening doesn’t make sense.  Then we can truly say we are more efficient – screening women more likely to benefit and NOT screening women more likely to be harmed.”


View the original article here

Accutane Update – Or How An Acne Problem Has Now Made Me a Vegan….

When I cruised on the Disney Fantasy back in March, I was completely and totally exhausted.  While my fellow Traveling Moms went to shows and hung out at the various clubs on board, I sat in bed watching Shark Tank and going to bed early.  I mentioned the exhaustion to my dermatologist but she wasn’t too concerned.

Until my blood work came back with high liver enzymes.  I was immediately taken off of Accutane for two weeks, and I found that the exhaustion lifted as soon as I stopped taking the pills.  I returned to the doctor this morning to find that my liver enzymes had returned to normal.

And then, she mentioned my cholesterol.  I’ve always had high cholesterol, and both of my parents and my sister have high cholesterol also.  Accutane also makes cholesterol rise.

“What are you eating?”, she asked, in a somewhat judgmental tone.  “Chicken, fish, fruit, rice…..”, I replied…. someone defensively.  I felt obese, overweight, unhealthy, and gross – in addition to having bad acne.

Then she put me on a vegan diet.  Vegan… as in no meat.  No fish. No cheese. No milk in my coffee.  How in the world do I eat vegan?  Any tips?

pixel Accutane Update Or How An Acne Problem Has Now Made Me a Vegan.... Tagged as: Accutane


View the original article here

Cardiobrief blog says NYT story on screening for student athletes “falls short in so many respects”

There may be no more horrifying medical catastrophe than the sudden death of a young athlete on the playing field in front of a large crowd of friends, family, and community. But it’s also a dizzyingly complex subject with no easy solutions. Experts are divided. The American Heart Association recently reaffirmed that it does not recommend universal screening for potential cardiovascular disease in young athletes with electrocardiograms (ECGs). On the other hand, universal screening has been adopted, apparently successfully, in Italy.

According to Anahad O’Connor in the New York Times, however, the movement toward routine ECG screening for student athletes may be inexorable, as it is not just cost-effective but desirable from a medical and a societal perspective. The Times article states that sudden cardiac death (SCD) of young athletes “is far more prevalent… than previously believed.” About 2,000 children each year die from SCD, according to the American Academy of Pediatrics, as cited by the Times, but this includes all children, not just athletes. The Times quotes the mother of a young athlete who died: “this happens all the time.”

But the world’s leading expert on SCD, Barry Maron, of the Minneapolis Heart Institute, insists that there has been no noticeable change in prevalence, and that SCD in children– whether athletes or not– is a rare event.  “The peer reviewed data on this topic suggests that there are about 75 sudden cardiovascular deaths in competitive atheltes every year in the US,” he told me in an interview. (The Times article is similarly dizzy about the cost of an ECG test. Although medical costs are always a byzantine topic, the $1,400 cost cited in the article is preposterous. Move the decimal point one place: $140 is a lot closer to reality.)

O’Connor acknowledges that the AHA does not recommend universal screening, but argues that the position “pivots on old data.” He cites a 2010 study from Stanford published in Annals of Internal Medicine suggesting that ECG screening may be cost-effective, but doesn’t cite an accompanying article in the same issue that reached a much less positive conclusion. Also not mentioned is an editorial accompanying the articles, written by Maron himself, offering a number of reasons why widespread ECG  screening should not be widely adopted at this time. (Click here for my previous coverage of the Annals articles.)

Even the Stanford author tells the Times that “we are not advocating this as a mandatory test for all students or all athletes,” but the article moves on to quote another expert who thinks “the time has come for thorough heart screenings for all young athletes.” James Willerson, of the Texas Heart Institute, told O’Connor: “If we save even one life, it will be worth it.” But Willerson, who had a distinguished career as a cardiology thought leader, is not an expert in SCD, and has an important conflict of interest in this case. As mentioned in the Times article, Willerson has a $5 million private grant to screen 10,000 students in Houston middle schools.

In his interview with me Maron offered a far more balanced perspective. He acknowledged that “each of these deaths are greatly tragic, and it is never the intention to minimize it by citing numbers, however large and however small. Furthermore,” he continued, “no one would ever feel comfortable placing a monetary value on a young athlete’s life.”

Maron spoke about the limitations that most cardiologists, Willerson aside, understand about ECGs. The test is far from perfect. There are false negative and false positive tests, and these need to be considered when evaluating the test. The high rate of false negatives associated with the ECG means that “in a significant proportion of the screened population important diseases would be expected to be missed,” said Maron. “This limitation is not even mentioned in the [Times] article.” False positives are also important, Maron observed, “because they create the possibility of unwarranted disqualification from sports as well as substantial anxiety among the families and participants.”

Another cardiologist, electrophysiologist Wes Fisher, talked about false positives in more graphic terms:

The psychological and emotional toll of telling a young student athlete that they can no longer partiipate in sports… is huge. Anyone who thinks it’s as easy as “just get an EKG” has never had to evaluate the marginal 18-year old who’s life you’ll potentially change forever.

Maron was also highly critical of the exclusive focus on student athletes:

All this discussion about limiting preparticipation screening for the detection of potentially lethal cardiovascular disease to athlete populations does not make a lot of sense because it is exclusionary and discriminatory. More sudden deaths from these same genetic diseases occur in nonathletes, numerically speaking. Therefore it would seem most prudent to discuss screening in young people, athletes and nonathletes, for these diseases. However, the numbers involved in those projected screening programs are so large that they limit any reasonable discussion of practicality.

According to Maron, there are about 10.7 million athletes out of a total population of 63 million children and adolescents.

On the same day as the Times article appeared, the AHA issued a science advisory about screening approaches for heart disease in children and adolescents. Once again, the AHA did not endorse mandatory screening for athletic participation. As Stuart Berger, one of the authors of the AHA statement, wrote:

New screening programs, including mass ECG screening, must be based on sound and evidence-based principles rather than a reaction to catastrophic events.

The Times article appears to be one of the first articles featured in the Times new “Well” blog, which is intended to bring substantially enhanced coverage of health topics onto the Times’ website. This article does not bode well for the future of this coverage, as it falls short in so many respects.


View the original article here

Cardiobrief blog says NYT story on screening for student athletes “falls short in so many respects”

There may be no more horrifying medical catastrophe than the sudden death of a young athlete on the playing field in front of a large crowd of friends, family, and community. But it’s also a dizzyingly complex subject with no easy solutions. Experts are divided. The American Heart Association recently reaffirmed that it does not recommend universal screening for potential cardiovascular disease in young athletes with electrocardiograms (ECGs). On the other hand, universal screening has been adopted, apparently successfully, in Italy.

According to Anahad O’Connor in the New York Times, however, the movement toward routine ECG screening for student athletes may be inexorable, as it is not just cost-effective but desirable from a medical and a societal perspective. The Times article states that sudden cardiac death (SCD) of young athletes “is far more prevalent… than previously believed.” About 2,000 children each year die from SCD, according to the American Academy of Pediatrics, as cited by the Times, but this includes all children, not just athletes. The Times quotes the mother of a young athlete who died: “this happens all the time.”

But the world’s leading expert on SCD, Barry Maron, of the Minneapolis Heart Institute, insists that there has been no noticeable change in prevalence, and that SCD in children– whether athletes or not– is a rare event.  “The peer reviewed data on this topic suggests that there are about 75 sudden cardiovascular deaths in competitive atheltes every year in the US,” he told me in an interview. (The Times article is similarly dizzy about the cost of an ECG test. Although medical costs are always a byzantine topic, the $1,400 cost cited in the article is preposterous. Move the decimal point one place: $140 is a lot closer to reality.)

O’Connor acknowledges that the AHA does not recommend universal screening, but argues that the position “pivots on old data.” He cites a 2010 study from Stanford published in Annals of Internal Medicine suggesting that ECG screening may be cost-effective, but doesn’t cite an accompanying article in the same issue that reached a much less positive conclusion. Also not mentioned is an editorial accompanying the articles, written by Maron himself, offering a number of reasons why widespread ECG  screening should not be widely adopted at this time. (Click here for my previous coverage of the Annals articles.)

Even the Stanford author tells the Times that “we are not advocating this as a mandatory test for all students or all athletes,” but the article moves on to quote another expert who thinks “the time has come for thorough heart screenings for all young athletes.” James Willerson, of the Texas Heart Institute, told O’Connor: “If we save even one life, it will be worth it.” But Willerson, who had a distinguished career as a cardiology thought leader, is not an expert in SCD, and has an important conflict of interest in this case. As mentioned in the Times article, Willerson has a $5 million private grant to screen 10,000 students in Houston middle schools.

In his interview with me Maron offered a far more balanced perspective. He acknowledged that “each of these deaths are greatly tragic, and it is never the intention to minimize it by citing numbers, however large and however small. Furthermore,” he continued, “no one would ever feel comfortable placing a monetary value on a young athlete’s life.”

Maron spoke about the limitations that most cardiologists, Willerson aside, understand about ECGs. The test is far from perfect. There are false negative and false positive tests, and these need to be considered when evaluating the test. The high rate of false negatives associated with the ECG means that “in a significant proportion of the screened population important diseases would be expected to be missed,” said Maron. “This limitation is not even mentioned in the [Times] article.” False positives are also important, Maron observed, “because they create the possibility of unwarranted disqualification from sports as well as substantial anxiety among the families and participants.”

Another cardiologist, electrophysiologist Wes Fisher, talked about false positives in more graphic terms:

The psychological and emotional toll of telling a young student athlete that they can no longer partiipate in sports… is huge. Anyone who thinks it’s as easy as “just get an EKG” has never had to evaluate the marginal 18-year old who’s life you’ll potentially change forever.

Maron was also highly critical of the exclusive focus on student athletes:

All this discussion about limiting preparticipation screening for the detection of potentially lethal cardiovascular disease to athlete populations does not make a lot of sense because it is exclusionary and discriminatory. More sudden deaths from these same genetic diseases occur in nonathletes, numerically speaking. Therefore it would seem most prudent to discuss screening in young people, athletes and nonathletes, for these diseases. However, the numbers involved in those projected screening programs are so large that they limit any reasonable discussion of practicality.

According to Maron, there are about 10.7 million athletes out of a total population of 63 million children and adolescents.

On the same day as the Times article appeared, the AHA issued a science advisory about screening approaches for heart disease in children and adolescents. Once again, the AHA did not endorse mandatory screening for athletic participation. As Stuart Berger, one of the authors of the AHA statement, wrote:

New screening programs, including mass ECG screening, must be based on sound and evidence-based principles rather than a reaction to catastrophic events.

The Times article appears to be one of the first articles featured in the Times new “Well” blog, which is intended to bring substantially enhanced coverage of health topics onto the Times’ website. This article does not bode well for the future of this coverage, as it falls short in so many respects.


View the original article here

Cardiobrief blog says NYT story on screening for student athletes “falls short in so many respects”

There may be no more horrifying medical catastrophe than the sudden death of a young athlete on the playing field in front of a large crowd of friends, family, and community. But it’s also a dizzyingly complex subject with no easy solutions. Experts are divided. The American Heart Association recently reaffirmed that it does not recommend universal screening for potential cardiovascular disease in young athletes with electrocardiograms (ECGs). On the other hand, universal screening has been adopted, apparently successfully, in Italy.

According to Anahad O’Connor in the New York Times, however, the movement toward routine ECG screening for student athletes may be inexorable, as it is not just cost-effective but desirable from a medical and a societal perspective. The Times article states that sudden cardiac death (SCD) of young athletes “is far more prevalent… than previously believed.” About 2,000 children each year die from SCD, according to the American Academy of Pediatrics, as cited by the Times, but this includes all children, not just athletes. The Times quotes the mother of a young athlete who died: “this happens all the time.”

But the world’s leading expert on SCD, Barry Maron, of the Minneapolis Heart Institute, insists that there has been no noticeable change in prevalence, and that SCD in children– whether athletes or not– is a rare event.  “The peer reviewed data on this topic suggests that there are about 75 sudden cardiovascular deaths in competitive atheltes every year in the US,” he told me in an interview. (The Times article is similarly dizzy about the cost of an ECG test. Although medical costs are always a byzantine topic, the $1,400 cost cited in the article is preposterous. Move the decimal point one place: $140 is a lot closer to reality.)

O’Connor acknowledges that the AHA does not recommend universal screening, but argues that the position “pivots on old data.” He cites a 2010 study from Stanford published in Annals of Internal Medicine suggesting that ECG screening may be cost-effective, but doesn’t cite an accompanying article in the same issue that reached a much less positive conclusion. Also not mentioned is an editorial accompanying the articles, written by Maron himself, offering a number of reasons why widespread ECG  screening should not be widely adopted at this time. (Click here for my previous coverage of the Annals articles.)

Even the Stanford author tells the Times that “we are not advocating this as a mandatory test for all students or all athletes,” but the article moves on to quote another expert who thinks “the time has come for thorough heart screenings for all young athletes.” James Willerson, of the Texas Heart Institute, told O’Connor: “If we save even one life, it will be worth it.” But Willerson, who had a distinguished career as a cardiology thought leader, is not an expert in SCD, and has an important conflict of interest in this case. As mentioned in the Times article, Willerson has a $5 million private grant to screen 10,000 students in Houston middle schools.

In his interview with me Maron offered a far more balanced perspective. He acknowledged that “each of these deaths are greatly tragic, and it is never the intention to minimize it by citing numbers, however large and however small. Furthermore,” he continued, “no one would ever feel comfortable placing a monetary value on a young athlete’s life.”

Maron spoke about the limitations that most cardiologists, Willerson aside, understand about ECGs. The test is far from perfect. There are false negative and false positive tests, and these need to be considered when evaluating the test. The high rate of false negatives associated with the ECG means that “in a significant proportion of the screened population important diseases would be expected to be missed,” said Maron. “This limitation is not even mentioned in the [Times] article.” False positives are also important, Maron observed, “because they create the possibility of unwarranted disqualification from sports as well as substantial anxiety among the families and participants.”

Another cardiologist, electrophysiologist Wes Fisher, talked about false positives in more graphic terms:

The psychological and emotional toll of telling a young student athlete that they can no longer partiipate in sports… is huge. Anyone who thinks it’s as easy as “just get an EKG” has never had to evaluate the marginal 18-year old who’s life you’ll potentially change forever.

Maron was also highly critical of the exclusive focus on student athletes:

All this discussion about limiting preparticipation screening for the detection of potentially lethal cardiovascular disease to athlete populations does not make a lot of sense because it is exclusionary and discriminatory. More sudden deaths from these same genetic diseases occur in nonathletes, numerically speaking. Therefore it would seem most prudent to discuss screening in young people, athletes and nonathletes, for these diseases. However, the numbers involved in those projected screening programs are so large that they limit any reasonable discussion of practicality.

According to Maron, there are about 10.7 million athletes out of a total population of 63 million children and adolescents.

On the same day as the Times article appeared, the AHA issued a science advisory about screening approaches for heart disease in children and adolescents. Once again, the AHA did not endorse mandatory screening for athletic participation. As Stuart Berger, one of the authors of the AHA statement, wrote:

New screening programs, including mass ECG screening, must be based on sound and evidence-based principles rather than a reaction to catastrophic events.

The Times article appears to be one of the first articles featured in the Times new “Well” blog, which is intended to bring substantially enhanced coverage of health topics onto the Times’ website. This article does not bode well for the future of this coverage, as it falls short in so many respects.


View the original article here

What is BB Cream? Video Post

You’ve probably heard about BB Cream – this popular Asian and European skin care product is making its way over here to the US, and many skin care lines are now offering their own version.  Check out this video for more information about BB Cream, how to use it, and how it differs from tinted moisturizer.

pixel What is BB Cream? Video Post Tagged as: BB cream, mom beauty


View the original article here

Grasping and even celebrating uncertainty

“…my anxiety about how we do clinical science overall is not new; this blog is overrun with it. However, the new branch of that anxiety relates to something I have termed “fast science.” Like fast food it fills us up, but the calories are at best empty and at worst detrimental. What I mean is that science is a process more than it is a result, and this process cannot and should not be microwaved….

So, let’s celebrate uncertainty. Let’s take time to question, answer and question again. Slow down, take a deep breath, cook a slow meal and think.”


View the original article here

Grasping and even celebrating uncertainty

“…my anxiety about how we do clinical science overall is not new; this blog is overrun with it. However, the new branch of that anxiety relates to something I have termed “fast science.” Like fast food it fills us up, but the calories are at best empty and at worst detrimental. What I mean is that science is a process more than it is a result, and this process cannot and should not be microwaved….

So, let’s celebrate uncertainty. Let’s take time to question, answer and question again. Slow down, take a deep breath, cook a slow meal and think.”


View the original article here

Grasping and even celebrating uncertainty

“…my anxiety about how we do clinical science overall is not new; this blog is overrun with it. However, the new branch of that anxiety relates to something I have termed “fast science.” Like fast food it fills us up, but the calories are at best empty and at worst detrimental. What I mean is that science is a process more than it is a result, and this process cannot and should not be microwaved….

So, let’s celebrate uncertainty. Let’s take time to question, answer and question again. Slow down, take a deep breath, cook a slow meal and think.”


View the original article here

I’m Featured on ConAgra’s “The Dish” Website

I’ve talked before about ConAgra’s new website – The Dish!  It’s a great place for bloggers and non-bloggers to get information about food and blogging.

For the next two months, I’m the featured blogger on the site, and my first post is up!  It’s titled Five Ways to Increase Your Blog Traffic, and I’d love for you to take a look at it and let me know what you think!

Disclosure: I was a consultant on the Dish, and received compensation for my role.

pixel Im Featured on ConAgras The Dish Website

View the original article here

I’ll take a pack of cigarettes, a large soda and a package of pork rinds

The following is a guest post by Harold DeMonaco, one of our expert editors on HealthNewsReview.org and Director of the Innovation Support Center at the Massachusetts General Hospital.

—————————————————————————–

While researching a totally different topic, I ran across a recent article published in the Journal of Occupational and Environmental Medicine. Researchers from the Mayo Clinic evaluated healthcare costs for employees and retirees of the Clinic who had continuous benefit coverage from 2001 through 2007. The Mayo Clinic funded the research project. Specifically, they looked at the incremental costs associated with obesity and with smoking. No surprises here, both increased healthcare costs. I found some of the data interesting.

The researchers collected data from a number of administrative sources including patient registration and information provided by employee patients during routine office visits.

Smoking status is routinely collected as part of office visits. The evaluation included over 25,000 current employees and about 5,500 retirees. The baseline characteristics of these healthcare workers are interesting in and of themselves.

Smoking status

No

Yes

Unknown

Employees

53.9%

13.3%

32.8%

Retirees

60.6%

17.5%

21.9%

Of those who responded, roughly one out of every eight employees smokes. Current and retiree employee healthcare costs were $1,274 (or 16%) and $1,401 (or about 12%) respectively more than their counterparts who do not smoke. There are probably other factors involved such as income and education, but the numbers speak for themselves. Smoking does add significantly to healthcare costs.

The researchers also looked at body mass index and healthcare costs. 57% of the current employees are overweight to morbidly obese as compared to 66% of retirees.

Body Mass Index

Overweight

Obese

Morbidly Obese 1

Morbidly Obese 2

Employee Costs

+$382

+$1,850

+$3,086

+$5,530

Retiree Costs

NS

NS

+$2,907

+$5,467

Like all studies, this one has several limitations. But the basic information is telling. According to Kaiser Family Foundation Minnesota is just about on average with the rest of the US in terms of overweight and obesity rates (63%). I’ll go out on a limb and suggest that the results are likely repeatable elsewhere. Healthcare workers don’t seem to be very good examples of a healthy lifestyle. It does not appear that we are taking our own advice.

Total healthcare costs exceeded $2.6 Trillion in 2010 or about 18% of our gross domestic product. We can expect those numbers to dramatically increase as the population ages, tobacco continues to be subsidized (to the tune of $194 Million in 2010) and our waistbands continue to expand. With the ongoing debate over Obamacare, I would have thought, as a non-journalist, that more in the mainstream media would have picked up on this story rather than chin implants.



View the original article here

I’ll take a pack of cigarettes, a large soda and a package of pork rinds

The following is a guest post by Harold DeMonaco, one of our expert editors on HealthNewsReview.org and Director of the Innovation Support Center at the Massachusetts General Hospital.

—————————————————————————–

While researching a totally different topic, I ran across a recent article published in the Journal of Occupational and Environmental Medicine. Researchers from the Mayo Clinic evaluated healthcare costs for employees and retirees of the Clinic who had continuous benefit coverage from 2001 through 2007. The Mayo Clinic funded the research project. Specifically, they looked at the incremental costs associated with obesity and with smoking. No surprises here, both increased healthcare costs. I found some of the data interesting.

The researchers collected data from a number of administrative sources including patient registration and information provided by employee patients during routine office visits.

Smoking status is routinely collected as part of office visits. The evaluation included over 25,000 current employees and about 5,500 retirees. The baseline characteristics of these healthcare workers are interesting in and of themselves.

Smoking status

No

Yes

Unknown

Employees

53.9%

13.3%

32.8%

Retirees

60.6%

17.5%

21.9%

Of those who responded, roughly one out of every eight employees smokes. Current and retiree employee healthcare costs were $1,274 (or 16%) and $1,401 (or about 12%) respectively more than their counterparts who do not smoke. There are probably other factors involved such as income and education, but the numbers speak for themselves. Smoking does add significantly to healthcare costs.

The researchers also looked at body mass index and healthcare costs. 57% of the current employees are overweight to morbidly obese as compared to 66% of retirees.

Body Mass Index

Overweight

Obese

Morbidly Obese 1

Morbidly Obese 2

Employee Costs

+$382

+$1,850

+$3,086

+$5,530

Retiree Costs

NS

NS

+$2,907

+$5,467

Like all studies, this one has several limitations. But the basic information is telling. According to Kaiser Family Foundation Minnesota is just about on average with the rest of the US in terms of overweight and obesity rates (63%). I’ll go out on a limb and suggest that the results are likely repeatable elsewhere. Healthcare workers don’t seem to be very good examples of a healthy lifestyle. It does not appear that we are taking our own advice.

Total healthcare costs exceeded $2.6 Trillion in 2010 or about 18% of our gross domestic product. We can expect those numbers to dramatically increase as the population ages, tobacco continues to be subsidized (to the tune of $194 Million in 2010) and our waistbands continue to expand. With the ongoing debate over Obamacare, I would have thought, as a non-journalist, that more in the mainstream media would have picked up on this story rather than chin implants.



View the original article here

I’ll take a pack of cigarettes, a large soda and a package of pork rinds

The following is a guest post by Harold DeMonaco, one of our expert editors on HealthNewsReview.org and Director of the Innovation Support Center at the Massachusetts General Hospital.

—————————————————————————–

While researching a totally different topic, I ran across a recent article published in the Journal of Occupational and Environmental Medicine. Researchers from the Mayo Clinic evaluated healthcare costs for employees and retirees of the Clinic who had continuous benefit coverage from 2001 through 2007. The Mayo Clinic funded the research project. Specifically, they looked at the incremental costs associated with obesity and with smoking. No surprises here, both increased healthcare costs. I found some of the data interesting.

The researchers collected data from a number of administrative sources including patient registration and information provided by employee patients during routine office visits.

Smoking status is routinely collected as part of office visits. The evaluation included over 25,000 current employees and about 5,500 retirees. The baseline characteristics of these healthcare workers are interesting in and of themselves.

Smoking status

No

Yes

Unknown

Employees

53.9%

13.3%

32.8%

Retirees

60.6%

17.5%

21.9%

Of those who responded, roughly one out of every eight employees smokes. Current and retiree employee healthcare costs were $1,274 (or 16%) and $1,401 (or about 12%) respectively more than their counterparts who do not smoke. There are probably other factors involved such as income and education, but the numbers speak for themselves. Smoking does add significantly to healthcare costs.

The researchers also looked at body mass index and healthcare costs. 57% of the current employees are overweight to morbidly obese as compared to 66% of retirees.

Body Mass Index

Overweight

Obese

Morbidly Obese 1

Morbidly Obese 2

Employee Costs

+$382

+$1,850

+$3,086

+$5,530

Retiree Costs

NS

NS

+$2,907

+$5,467

Like all studies, this one has several limitations. But the basic information is telling. According to Kaiser Family Foundation Minnesota is just about on average with the rest of the US in terms of overweight and obesity rates (63%). I’ll go out on a limb and suggest that the results are likely repeatable elsewhere. Healthcare workers don’t seem to be very good examples of a healthy lifestyle. It does not appear that we are taking our own advice.

Total healthcare costs exceeded $2.6 Trillion in 2010 or about 18% of our gross domestic product. We can expect those numbers to dramatically increase as the population ages, tobacco continues to be subsidized (to the tune of $194 Million in 2010) and our waistbands continue to expand. With the ongoing debate over Obamacare, I would have thought, as a non-journalist, that more in the mainstream media would have picked up on this story rather than chin implants.



View the original article here

Wordless Wednesday: The Versace Mansion

Sorry, I could not read the content fromt this page.

View the original article here

Everyday Health Editors' Product Review Blog

Reuters: Business Travel

MedicineNet Nutrition, Food and Recipes General

Pages

MedicineNet Diet and Weight Management General

Frommer's Deals and News

Behind the Guides

Media Releases: News Desk

About.com Day Trading

Frommers.com Cruise Blog

Arthur Frommer Online

Dictionary.com Word of the Day

The Full Feed from HuffingtonPost.com